Do analysts rate TMDIF or NYXH?

Nyxoah has a consensus price target of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation & earnings, TMDIF or NYXH?

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.85 $6.95M $0.05 2.64 Nyxoah $11.33M 6.02 -$101.92M -$2.52 N/A

Is TMDIF or NYXH more profitable?

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Nyxoah -443.16% -178.90% -81.83%

Which has higher valuation & earnings, TMDIF or HSAQ?

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.85 $6.95M $0.05 2.64 Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Is TMDIF or HSAQ more profitable?

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Do analysts rate DXR or TMDIF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, DXR or TMDIF?

Titan Medical has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Titan Medical $17.63M 0.85 $6.95M $0.05 2.64

Is DXR or TMDIF more profitable?

Daxor's return on equity of 0.00% beat Titan Medical's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Titan Medical N/A -82.31% -51.47%

Do analysts prefer TMDIF or RNXT?

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 258.65%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better valuation & earnings, TMDIF or RNXT?

Titan Medical has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.85 $6.95M $0.05 2.64 RenovoRx $1.12M 95.50 -$11.17M -$0.31 N/A

Is TMDIF or RNXT more profitable?

Titan Medical has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. Titan Medical's return on equity of -82.31% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% RenovoRx -621.71% -135.11% -101.91%

Do analysts prefer TMDIF or COCH?

Envoy Medical has a consensus target price of $2.00, suggesting a potential upside of 173.94%. Given Envoy Medical's stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Envoy Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Titan Medical (TMDIF) Competitors

$0.13 +0.02 (+13.59%)

As of 09/2/2026

Compare

TMDIF vs. NYXH, HSAQ, DXR, RNXT, and COCH

Should you buy Titan Medical stock or one of its competitors? Titan Medical's main competitors and comparable companies include Nyxoah (NYXH), Health Sciences Acquisitions Co. 2 (HSAQ), Daxor (DXR), RenovoRx (RNXT), and Envoy Medical (COCH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Titan Medical compare to Nyxoah?

Titan Medical (NASDAQ:TMDIF) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Nyxoah had 4 more articles in the media than Titan Medical. MarketBeat recorded 4 mentions for Nyxoah and 0 mentions for Titan Medical. Nyxoah's average media sentiment score of 0.33 beat Titan Medical's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Nyxoah	Neutral

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64
Nyxoah	$11.33M	6.02	-$101.92M	-$2.52	N/A

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Nyxoah	-443.16%	-178.90%	-81.83%

Nyxoah has a consensus price target of $4.26, suggesting a potential upside of 142.16%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

0.0% of Titan Medical shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Titan Medical and Nyxoah tied by winning 8 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Health Sciences Acquisitions Co. 2?

Titan Medical (NASDAQ:TMDIF) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 0.0% of Titan Medical shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Summary

Health Sciences Acquisitions Co. 2 beats Titan Medical on 4 of the 7 factors compared between the two stocks.

How does Titan Medical compare to Daxor?

Daxor (NASDAQ:DXR) and Titan Medical (NASDAQ:TMDIF) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Titan Medical has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64

Daxor's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Titan Medical	N/A	-82.31%	-51.47%

Daxor has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

1.3% of Daxor shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Daxor had 2 more articles in the media than Titan Medical. MarketBeat recorded 2 mentions for Daxor and 0 mentions for Titan Medical. Titan Medical's average media sentiment score of 0.00 beat Daxor's score of -1.50 indicating that Titan Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Daxor	Very Negative
Titan Medical	Neutral

Summary

Daxor beats Titan Medical on 7 of the 10 factors compared between the two stocks.

How does Titan Medical compare to RenovoRx?

Titan Medical (NASDAQ:TMDIF) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

RenovoRx has a consensus target price of $8.50, indicating a potential upside of 258.65%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Titan Medical has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. Titan Medical's return on equity of -82.31% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
RenovoRx	-621.71%	-135.11%	-101.91%

Titan Medical has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64
RenovoRx	$1.12M	95.50	-$11.17M	-$0.31	N/A

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 0.0% of Titan Medical shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, RenovoRx had 11 more articles in the media than Titan Medical. MarketBeat recorded 11 mentions for RenovoRx and 0 mentions for Titan Medical. RenovoRx's average media sentiment score of 0.90 beat Titan Medical's score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
RenovoRx	Positive

Summary

RenovoRx beats Titan Medical on 9 of the 17 factors compared between the two stocks.

How does Titan Medical compare to Envoy Medical?

Titan Medical (NASDAQ:TMDIF) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 7.1% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Titan Medical has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64
Envoy Medical	$240K	234.82	-$23.76M	-$0.76	N/A

Envoy Medical has a consensus target price of $2.00, suggesting a potential upside of 173.94%. Given Envoy Medical's stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Titan Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Envoy Medical	-11,304.83%	N/A	-144.13%

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled Envoy Medical'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Envoy Medical	Neutral

Summary

Envoy Medical beats Titan Medical on 8 of the 14 factors compared between the two stocks.

Get Titan Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDIF vs. The Competition

Export

Metric	Titan Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.06M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.11	25.93	273.28	25.38
Price / Sales	0.85	73.29	613.48	92.60
Price / Cash	0.02	33.14	77.82	52.26
Price / Book	0.13	6.04	12.89	6.14
Net Income	$6.95M	$150.03M	$3.47B	$349.01M
7 Day Performance	7.02%	-1.30%	0.61%	-0.27%
1 Month Performance	-7.62%	1.29%	5.73%	0.68%
1 Year Performance	-60.84%	9.89%	25.37%	14.84%

Titan Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDIF Titan Medical	N/A	$0.13 +13.6%	N/A	-60.8%	$15.06M	$17.63M	N/A	50
NYXH Nyxoah	2.7788 of 5 stars	$1.63 +1.6%	$4.26 +162.3%	-70.1%	$62.99M	$11.33M	N/A	110	News Coverage Gap Up
HSAQ Health Sciences Acquisitions Co. 2	N/A	$5.36 -1.3%	N/A	+80.7%	$60.10M	N/A	N/A	4
DXR Daxor	1.3616 of 5 stars	$10.05 +0.5%	N/A	-0.8%	$58.66M	N/A	N/A	37	Negative News
RNXT RenovoRx	2.9902 of 5 stars	$1.29 -2.7%	$8.50 +561.5%	+89.6%	$57.99M	$1.12M	N/A	6	Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDIF) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Titan Medical (TMDIF) Competitors

TMDIF vs. NYXH, HSAQ, DXR, RNXT, and COCH

How does Titan Medical compare to Nyxoah?

Summary

How does Titan Medical compare to Health Sciences Acquisitions Co. 2?

Summary

How does Titan Medical compare to Daxor?

Summary

How does Titan Medical compare to RenovoRx?

Summary

How does Titan Medical compare to Envoy Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Titan Medical (TMDIF) Competitors

TMDIF vs. NYXH, HSAQ, DXR, RNXT, and COCH

How does Titan Medical compare to Nyxoah?

Does the media favor TMDIF or NYXH?

Which has more risk & volatility, TMDIF or NYXH?

Which has preferable valuation & earnings, TMDIF or NYXH?

Is TMDIF or NYXH more profitable?

Do analysts rate TMDIF or NYXH?

Do insiders and institutionals have more ownership in TMDIF or NYXH?

Summary

How does Titan Medical compare to Health Sciences Acquisitions Co. 2?

Is TMDIF or HSAQ more profitable?

Do institutionals & insiders have more ownership in TMDIF or HSAQ?

Which has more volatility & risk, TMDIF or HSAQ?

Which has higher valuation & earnings, TMDIF or HSAQ?

Does the media favor TMDIF or HSAQ?

Summary

How does Titan Medical compare to Daxor?

Which has higher valuation and earnings, DXR or TMDIF?

Is DXR or TMDIF more profitable?

Which has more volatility and risk, DXR or TMDIF?

Do analysts rate DXR or TMDIF?

Do insiders & institutionals hold more shares of DXR or TMDIF?

Does the media refer more to DXR or TMDIF?

Summary

How does Titan Medical compare to RenovoRx?

Do analysts prefer TMDIF or RNXT?

Which has more risk and volatility, TMDIF or RNXT?

Is TMDIF or RNXT more profitable?

Which has better valuation & earnings, TMDIF or RNXT?

Do insiders and institutionals have more ownership in TMDIF or RNXT?

Does the media prefer TMDIF or RNXT?

Summary

How does Titan Medical compare to Envoy Medical?

Do institutionals and insiders hold more shares of TMDIF or COCH?

Which has higher earnings & valuation, TMDIF or COCH?

Do analysts prefer TMDIF or COCH?

Is TMDIF or COCH more profitable?

Which has more risk & volatility, TMDIF or COCH?

Does the media favor TMDIF or COCH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools